Tesofensine
500mcg
Tesofensine 500mcg
New Releases

Tesofensine

Monoamine Reuptake Inhibitor Research

$300.00
Third-Party Lab Tested
COA With Every Order
Fast U.S. Shipping
Text Email

What It Is

A triple monoamine reuptake inhibitor (DAT, NET, SERT) originally developed by NeuroSearch as a candidate for neurodegenerative disease research. Studied in published clinical and preclinical literature for its effects on energy balance and hypothalamic monoamine signaling pathways.

How It Works

1
Tesofensine binds DAT, NET, and SERT transporters
2
Synaptic reuptake of monoamines is blocked
3
Extracellular monoamine concentrations rise
4
Hypothalamic appetite circuits are studied

What Researchers Study It For

Energy balance preclinical research
Hypothalamic monoamine signaling studies
Dopaminergic & noradrenergic pathway models
Appetite regulation & body composition studies

Common Research Protocols

Published clinical and preclinical studies have administered tesofensine orally at microgram-to-milligram daily doses, with endpoints measured in body composition, resting energy expenditure, and serum monoamine metabolites. The long elimination half-life supports once-daily dosing schedules in published research.

Community Interest Areas

The obesity and energy-balance research community has focused on tesofensine because its triple-uptake-inhibitor profile (DAT/NET/SERT) produces a different pharmacological signature than single-target appetite suppressants — providing a probe for studying combined monoaminergic effects on satiety, metabolic rate, and central reward circuits. Originally developed for neurodegenerative disease research, the energy-balance effects emerged as an unexpected finding in those trials.

Triple Reuptake DAT, NET, and SERT inhibition
Long Half-Life ~9-day t½ enables once-daily dosing in published research

For research purposes only. Not intended for consumption, clinical application, or diagnostic use.